BC Platforms and NTT Group Soon to Inaugurate Debut of Japanese Precision Medicine Platform

BC Platforms and NTT Group Soon to Inaugurate Debut of Japanese Precision Medicine Platform

By, Admin 16 April 2024

BC Platforms and NTT Group Announce Inaugural Ceremony for Exclusive Collaboration and Debut of Japanese Precision Medicine Platform

Overview

BC Platforms (BCP) and NTT Life Science Corporation have teamed up in an exclusive partnership to advance data-driven medicine, particularly in Japan. The collaboration, which was officially inaugurated at a joint facility opening ceremony in Tokyo, aims to spearhead the Japan Precision Medicine PlatformTM (JPP), facilitating the secure and efficient use of clinical data across the nation.

Rights Post Partnership

  • This partnership, announced in October 2023, grants BCP and NTT exclusive rights within the Japanese market under the JPP umbrella. 
  • Through a multiyear effort, the platform will integrate, curate, and harmonize healthcare data, fostering collaboration among researchers to accelerate the development of new therapies.

For Positive Impact on Patient Care

  • Laurent Samama, Chairman of the Board at BCP, expressed enthusiasm for the partnership, emphasizing its role in scaling up their capabilities and maximizing their value proposition. 
  • The collaboration targets a positive impact on patient care through personalized medicine, utilizing real-world data to identify suitable candidates for clinical trials.

Strategic Goal of NTT

  • NTT's strategic goal of creating value through data-driven technology aligns with this partnership, as outlined in their medium-term management strategy. 
  • Akiko Kudo of NTT emphasized the importance of quickly establishing a market presence alongside BCP, a globally recognized player in the medical field.

Words from CEO: NTT Life Science

Kouji Korekawa, President and CEO of NTT Life Science, highlighted their commitment to revolutionizing healthcare solutions, drawing upon their extensive experience in medical research. Leveraging their existing network and expertise, they aim to drive adoption of the JPP across Japan.

Aim of This Collaboration

  • • Nino da Silva, Managing Director APAC at BC Platforms, underscored the combined strength of NTT's infrastructure and BCP's technology in building a robust medical data ecosystem. 
  • • The collaboration aims to provide unparalleled access to real-world data for global pharmaceutical companies and research organizations.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!